What are the indications, recommended dosing, contraindications, and common adverse effects of fluvoxamine?

Fluvoxamine: Clinical Overview

Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) FDA-approved for obsessive-compulsive disorder (OCD), with established efficacy in anxiety disorders including social anxiety, generalized anxiety, separation anxiety, and panic disorder in both adults and children/adolescents. 1

Indications

FDA-Approved

• Obsessive-Compulsive Disorder (OCD) in adults and children 2

Evidence-Based Off-Label Uses

• Anxiety disorders (social anxiety, generalized anxiety, separation anxiety, panic disorder) in patients aged 6-18 years 1
• Depression in adults 3
• Post-traumatic stress disorder (PTSD) with associated nightmares 4
• Social phobia in adults 5

Dosing Recommendations

Adults

• Starting dose: 50 mg twice daily 3, 6
• Effective dose range: 150-300 mg/day 3, 6
• Maximum dose: 300 mg/day (manufacturer recommendation) 2, though doses up to 600 mg/day have been tolerated in treatment-resistant cases 7
• Titration: Increase by 50 mg increments every 5-7 days as tolerated 3
• Dosing schedule: Twice-daily dosing required at any dose due to shorter half-life 1

Children and Adolescents (6-11 years)

• Starting dose: 25 mg at bedtime
• Maximum dose: 200 mg/day (steady-state concentrations are 2-3 times higher than in adolescents) 8

Adolescents (12-17 years)

• Starting dose: 25 mg at bedtime
• Maximum dose: 300 mg/day (similar pharmacokinetics to adults) 8
• Titration: Increase by 25 mg every 4-7 days 9

Special Populations

• Elderly patients: Start at lower doses; monitor closely for adverse effects 3
• Hepatic/renal impairment: Dose reduction recommended 1

Contraindications

Absolute Contraindications

• Concomitant use with MAOIs (including phenelzine, isocarboxazid, moclobemide, isoniazid, linezolid) - risk of fatal serotonin syndrome 1, 9
• Within 14 days of MAOI discontinuation 9

Relative Contraindications/Cautions

• Long QT syndrome (though less concern than with citalopram) 1
• Seizure disorders 1
• Bleeding disorders or concomitant anticoagulant use 1

Drug Interactions

Fluvoxamine has the highest potential for drug-drug interactions among SSRIs due to extensive CYP450 inhibition 1. It inhibits:

• CYP1A2 (potent)
• CYP2C19 (moderate)
• CYP2C9 (moderate)
• CYP3A4 (moderate)
• CYP2D6 (weak) 1

Critical Drug Interactions

Benzodiazepines:

• Alprazolam: Reduce dose by 50%; plasma concentrations double with fluvoxamine co-administration 2
• Triazolam: Exercise extreme caution 3
• Diazepam: Co-administration generally NOT advisable; clearance reduced by 65% 2

Other Medications:

• Theophylline: Reduce dose to one-third; clearance decreases 3-fold 2
• Warfarin: Increases warfarin concentrations by 98%; monitor INR closely 2
• Mexiletine: Clearance reduced by 38%; monitor serum levels 2

Serotonergic Drugs: Avoid combining with other serotonergic agents (SSRIs, SNRIs, TCAs, tramadol, meperidine, methadone, fentanyl, dextromethorphan, triptans, St. John's wort, tryptophan) due to serotonin syndrome risk 1

Common Adverse Effects

Most Frequent (≥5% and twice placebo rate) 2

• Gastrointestinal: Nausea (most common, 9% vs 1% placebo), dyspepsia, anorexia, vomiting, diarrhea
• CNS: Somnolence (22% vs 8% placebo), insomnia (21% vs 10% placebo), nervousness (12% vs 5% placebo), dizziness (11% vs 6% placebo), headache
• Other: Asthenia, sweating (7% vs 3% placebo), tremor (5% vs 1% placebo)
• Sexual dysfunction: Abnormal ejaculation (8% vs 1% in males) 2

Pediatric-Specific Adverse Effects 8

• Abdominal discomfort (more common than placebo)
• Increased motor activity
• Decreased appetite
• Most adverse events similar to adults

Serious Adverse Effects

Black Box Warning: Increased risk of suicidal thinking and behavior in children, adolescents, and young adults up to age 24 1, 9. Pooled absolute risk: 1% (antidepressant) vs 0.2% (placebo); NNH = 143 1

Serotonin Syndrome: Life-threatening condition with mental status changes, autonomic instability, neuromuscular aberrations, and GI symptoms. Occurs within 24-48 hours of combining serotonergic drugs 1, 2

Discontinuation Syndrome: Characterized by dizziness, fatigue, myalgias, nausea, insomnia, paresthesias, anxiety, and agitation. Fluvoxamine has moderate risk (less than paroxetine, more than fluoxetine) 1

Other Serious Events:

• Behavioral activation/agitation 1
• Hypomania/mania 1
• Abnormal bleeding (especially with NSAIDs/aspirin) 1
• Seizures 1

Clinical Management Pearls

Initiation

• Start with subtherapeutic "test" dose to minimize initial anxiety/agitation 1
• Titrate slowly at 1-2 week intervals for shorter half-life SSRIs 1
• Twice-daily dosing required (unlike most SSRIs) due to pharmacokinetics 1

Monitoring

• Close monitoring required in first weeks, especially after dose changes 9
• Monitor for suicidality particularly in first months and after dosage adjustments 1, 9
• Telephone contact acceptable for monitoring (not necessarily face-to-face) 9
• Therapeutic response timeline: Statistically significant improvement by 2 weeks, clinically significant by 6 weeks, maximal by 12+ weeks 1

Discontinuation

• Taper slowly over 10-14 days to minimize withdrawal symptoms 3, 9
• Never abruptly discontinue due to discontinuation syndrome risk 1

Treatment Duration

• Minimum adequate trial: 10-12 weeks at therapeutic dose 1
• Maintenance therapy: May reduce relapse rates in OCD (up to 67% of patients) 10
• Reassess need after 9 months with dosage reduction 3

Common Pitfalls

1. Underdosing: Effective doses (150-300 mg/day) often higher than starting doses; inadequate trials common
2. Premature discontinuation: Must allow 10-12 weeks at adequate dose before declaring treatment failure 1
3. Ignoring drug interactions: Fluvoxamine has MORE CYP450 interactions than other SSRIs 1
4. Single daily dosing: Unlike other SSRIs, fluvoxamine requires twice-daily dosing 1
5. Inadequate monitoring: Black box warning mandates close observation, especially early in treatment 9
6. Combining with benzodiazepines without dose adjustment: Particularly dangerous with alprazolam and diazepam 2

Special Considerations

Pregnancy/Lactation: Not studied in pregnant/postpartum women in clinical trials, though widely used 11

Elderly: Lower doses recommended; higher risk of neurotoxicity and adverse effects 3

Pediatric dosing differences: Children (6-11 years) achieve 2-3× higher plasma concentrations than adolescents, necessitating lower maximum doses 8